1. Volume 91, Issue 3, (December 2003)
Erratum to “First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up” 
Keiichi Fujiwara, Noriaki Sakuragi, Sachiko Suzuki, Nobutaka Yoshida, Kenichiro Maehata, Masashi Nishiya, Takayuki Koshida, Hideaki Sawai, Eriko Aotani, Ichiro Kohno 
Gynecologic Oncology 
Volume 91, Issue 3, (December 2003)
DOI: /j.ygyno

2. Fig. 2
(a) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in patients with stage III/IV disease. (b) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in stage III/IV patients with residual disease <2 cm. (c) Overall survival based on the dose of carboplatin (either <400 mg/m2 or ≥400 mg/m2) in stage III/IV patients with residual disease ≥2 cm.
Gynecologic Oncology  , DOI: ( /j.ygyno )